The other day, I linked to David Williams' insightful post countering the conventional EpiPen narrative. Turns out there's even more fallout:
"Mylan, said that the generic EpiPen would be available in several weeks and be identical to the existing product, which is used to treat severe allergic reactions. But it would have a wholesale list price of $300 for a pack of two, compared with just above $600 for the existing product."
As a friend noted today on Twitter, it's unclear on how they're going to compete with themselves and still come out ahead.
Not my monkeys, not my circus.
"Mylan, said that the generic EpiPen would be available in several weeks and be identical to the existing product, which is used to treat severe allergic reactions. But it would have a wholesale list price of $300 for a pack of two, compared with just above $600 for the existing product."
As a friend noted today on Twitter, it's unclear on how they're going to compete with themselves and still come out ahead.
Not my monkeys, not my circus.
[Hat Tip: Co-Blogger Bob V]
No comments:
Post a Comment